CMS Proposes Reviving Medicare Advantage Audit Rule as Insurer Shares Slide for a Second Day

The proposal would let auditors project sample findings back to 2018 across whole contracts, repricing audit exposure for the sector's largest plans.

Sources

Sources & evidence

What “Source checked” means

UNHLatest quoteHUMLatest quoteCVSLatest quote

UnitedHealth shares fell 10.2% on Wednesday as investors weighed a proposed Medicare audit expansion.

The Centers for Medicare and Medicaid Services issued the proposed rule on Monday, November 16, 2026. It is called CRUSH, for Comprehensive Regulations to Uncover Suspicious Healthcare.

The proposal is not in effect. CMS will accept public comment for 60 days after Federal Register publication, with comments due January 19, 2027.

A second-day selloff across the sector

UnitedHealth (NYSE: UNH) closed Wednesday down 10.2% at $349.91. Humana (NYSE: HUM) fell 13% to $385.78, and CVS Health (NYSE: CVS) fell 5.2% to $81.35.

Raymond James analyst Chris Meekins said news on both fronts appeared to be hitting the sector. The second front was Senator Bernie Sanders' Medicare for All push, outlined Wednesday in an Associated Press interview.

Those proposals are, in his words, “materially different from immediately eliminating private insurance.” They also differ from immediately moving provider reimbursement toward Medicare rates.

The audit core: no adjuster, extrapolation to 2018

The financial core is the RADV program, CMS's audit check on plan diagnoses. RADV is short for Risk Adjustment Data Validation.

CMS describes RADV as its primary way to address overpayments to Medicare Advantage organizations. It identifies diagnoses reported for risk adjustment that medical records do not support.

The proposal would codify that CMS would not apply a fee-for-service adjuster. The FFS adjuster is an error allowance for traditional Medicare claims.

CMS would also determine the sampling methodology itself, and it would begin extrapolating audit findings with payment year 2018 audits. Extrapolation projects findings from an audited sample across an entire contract.

CMS estimates the approach would let it collect about $9 billion per payment year. The figure is an agency estimate inside a proposal, not a booked recovery.

CMS states the core test plainly: “The core component of a RADV audit is to ensure that all diagnoses are properly supported by medical records.”

Nearly $90 billion is the proposal's own arithmetic

Taken together, the quantified provisions carry nearly $90 billion in estimated federal savings. CMS puts the costs at about $378.51 million, from 2027 to 2036.

Oppenheimer's Michael Wiederhorn read the savings narrowly. Nearly the entire amount reflects recoveries from Medicare Advantage plans, he wrote, per Barron's.

The savings are not spread across federal healthcare programs in that reading. Wiederhorn added that insurers could price the exposure into future annual bids to preserve margins.

“The ultimate financial impact remains uncertain and subject to final rulemaking and potential litigation,” Mizuho wrote. It called the proposal an important area to watch for Humana, UnitedHealth and CVS.

A vacated rule, an appeal, and a fresh attempt

In 2023, CMS finalized a RADV rule that eliminated the FFS adjuster and allowed extrapolation from payment year 2018.

Humana sued in September 2023. On September 25, 2025, Chief Judge Reed O'Connor vacated the rule in Humana v. Becerra.

The court held that dropping the adjuster was not a logical outgrowth of the proposed rule. The public had no meaningful chance to comment on that reasoning, an Administrative Procedure Act defect.

The court did not rule on the arbitrary-and-capricious merits. HHS appealed in November 2025, and the Fifth Circuit heard arguments in October 2026.

No decision had been reported in the sources read. CMS has continued auditing: it began payment year 2020 audits in March 2026, per Becker's, and has not decided whether to extrapolate those findings.

CRUSH would effectively revive the vacated rule's core through fresh rulemaking. A new notice-and-comment record is the procedural answer to the vacatur.

Mandatory fraud referrals and wider enrollment screening

The proposal also makes fraud referrals mandatory for Medicare Advantage organizations and Part D sponsors. Today, CMS only encourages those referrals.

In calendar 2025, only 46% of Part C and Part D contracts voluntarily reported such referrals. Only 19% reported any payment suspensions based on credible fraud allegations.

Suspension reporting would expand from pharmacies to all provider and supplier types.

The proposal would also require providers who bill Medicare Advantage plans to be enrolled in Original Medicare in an approved status.

Enrollment would let CMS apply full screening: identity verification, licensure review, site visits and fingerprint-based background checks.

If finalized, it would take effect on the first day of the plan year beginning two years after the final rule is published.

Other legs are narrower: 30-day reporting of enrollment changes, a wider ban on unsolicited supplier contact, and a formal hardship-exception framework. The contact ban would extend to texts, social messages, email and door-to-door visits; the hardship process exists today only in sub-regulatory guidance.

The wider rule reaches Medicaid, CHIP and the Marketplace, following a February 2026 request for information that drew more than 560 comments.

Insurers are mostly silent so far

Humana offered no comment on the proposal, per Barron's. UnitedHealth did not comment either.

A CVS spokesperson gave no specific comment on CRUSH. “We are confident in our risk-adjustment program and practices, including how we submit, audit and review codes,” the spokesperson said.

AHIP, the industry group, said it is closely reviewing the proposed rule. Its spokesman said plans share the goal of combatting waste, fraud and abuse while ensuring MA provides better care at lower costs for the 36 million Americans who choose it.

What remains unknown

What remains unknown starts with the final rule's shape: CMS may change the proposal after comments close on January 19, 2027.

Whether the Fifth Circuit revives the 2023 rule is also unknown; the appeal was argued in October 2026 and remains pending.

The savings path is unproven as well: nearly $90 billion is an estimate, and CMS is asking commenters to test its accuracy.

How much of the exposure insurers can price into future bids is unknown. Oppenheimer raised the possibility; no bid reflecting CRUSH exists yet.

The tests that come next

The first watch is the comment record, closing January 19, 2027. A final rule that differs from the proposal would reset the exposure math.

The second watch is the Fifth Circuit, whose decision on the 2023 vacatur could reshape CRUSH's procedural path.

The third watch is litigation if CRUSH is finalized. Mizuho flagged potential litigation as part of the uncertainty investors now carry.

The fourth watch is the next annual bid cycle, where any pricing of audit exposure would show first.

Sources & evidence

Source checked5 sources · 13 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 10.2 UnitedHealth share price change, Wednesday close (Barron's settled vintage)

    As of Nov. 18, 2026

  • $349.91 UnitedHealth share price, Wednesday close (Barron's settled vintage)

    As of Nov. 18, 2026

  • 13 Humana share price change, Wednesday close (Barron's settled vintage)

    As of Nov. 18, 2026

  • $385.78 Humana share price, Wednesday close (Barron's settled vintage)

    As of Nov. 18, 2026

  • 5.2 CVS Health share price change, Wednesday close (Barron's settled vintage)

    As of Nov. 18, 2026

  • $81.35 CVS Health share price, Wednesday close (Barron's settled vintage)

    As of Nov. 18, 2026

  • 36 Medicare Advantage enrollment cited by AHIP

    As of Nov. 18, 2026

Centers for Medicare & Medicaid Services

CRUSH Proposed Rule Fact Sheet (CMS-6098-P), CMS

  • $90B CMS estimated federal savings, CRUSH quantified provisions, 2027-2036 (CMS estimate in a proposed rule)

    As of Nov. 18, 2026

  • $9B CMS estimated Medicare Advantage overpayments collectable per payment year under the RADV proposal (CMS estimate)

    As of Nov. 18, 2026

  • $378.51M CMS estimated costs, CRUSH quantified provisions, 2027-2036

    As of Nov. 18, 2026

  • 46 Share of Medicare Part C and Part D contracts voluntarily reporting fraud referrals, calendar 2025

    As of Nov. 18, 2026

  • 19 Share of Medicare Part C and Part D contracts reporting payment suspensions on credible fraud allegations, calendar 2025

    As of Nov. 18, 2026

  • 560 Comments on the February 2026 CRUSH request for information

    As of Nov. 18, 2026

As of Wednesday, Nov. 18, 2026.

TickerGrove house illustration for policy coverage: the scales of justice

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories